Eli Lilly is making headlines with its experimental GLP-1 weight loss pill, orforglipron, which could soon offer a needle-free alternative to popular injectable drugs like Ozempic and Mounjaro. In a recent Phase trial, people with type diabetes taking orforglipron lost an average of nearly 8% of their body weight—about pounds—over weeks. The pill also significantly lowered A1C levels, a key marker for diabetes control.
Unlike current oral GLP-1 options, orforglipron does not require strict food or water restrictions, making it more convenient for patients. The most common side effects reported were mild to moderate digestive issues, such as nausea and diarrhea, similar to those seen with injectable GLP-1 drugs.
Eli Lilly plans to seek FDA approval for orforglipron as a diabetes treatment in and aims to pursue global approval for weight management by the end of this year. If approved, the company expects to launch the pill without the supply constraints that have plagued injectable GLP-1 medications.
Analysts believe orforglipron could be as effective as current injectable treatments, potentially reshaping the booming weight loss drug market and making these therapies more accessible to millions who prefer pills over injections.
